Image SHA-256 — or-diabetes-mech.png
22fdbfa99a402e0bafe6253e9f92eeebffb41648437ca7a74764c03411d127b1
Licensed Research: Diabetes Mechanism Analysis
$42.5K
In stock
SKU
OR-DIABETES-MECH
Leave blank to use the product price.
Computational research findings on the elemental signatures correlated with type-2 diabetes biology. Licensed transfer; patent-pending; not medical advice; not a cure.
First to market
Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.
First posted:
·
Last updated:
This item is delivered by Christopher Gabriel Brown by email within 24 hours of your order. You'll receive the deliverable at the email on your order. USA delivery only. Founder Access Pass credit (code FAP99CREDIT) applies at checkout automatically.
Licensed Research · Alchemy Data V2 Elemental Discovery · Patent-pending · USA only
License fee
$42,500.00 USD — Licensed transfer to a named USA buyer entity.
License terms (IP-retained model)
A purchase conveys the research package (data, formulation, patent application,
drawings, scripts) plus worldwide commercialization rights to the
named buyer entity. Patents and underlying IP are retained by
Christopher Gabriel Brown and are NOT sold. Buyer of record must be a
USA entity (up to 4 entities, joint & several). All sales final, non-refundable.
All inquiries by email and postal mail only — no phone calls, no brokers,
no intermediaries.
Diabetes Mechanism Analysis
Computational research findings — NOT medical advice, NOT clinically tested, NOT FDA-approved, NOT a cure. A computational discovery of the elemental signatures correlated with type-2 diabetes biology, evidence-graded against 20+ years of peer-reviewed research. Supplement-grade research; not a replacement for prescribed diabetes medication.
| Product | Licensed Research: Diabetes Mechanism Analysis |
| System | Alchemy Data V2 — 24.4M+ element combinations vs 257,500 synthesis methods |
| Lead finding | Zinc-amino acid architecture (C-H-O-N-Zn) as highest-signal class |
| IP posture | Patent application prepared (20 claims), ready to file |
| License fee | $42,500.00 USD — Licensed transfer |
New companion: see where this sits on the real FDA approval road — The Diabetes Discovery on the Real FDA Road explains what it would take to turn this into an approved medicine, and the one lawful way to make it as a dietary supplement. Available in the same category: cri-one.com/store/licensed-research.html.
01 Top discoveries — evidence graded
| Compound | Grade | Key role |
| C-H-O-N-Zn | B+ | Insulin-mimetic activity; PTP1B inhibition; GLUT-4 support |
| C-H-O-N-Mg | A− | Glucose metabolism; insulin sensitivity; ~30% of diabetics are Mg-deficient |
| C-H-O-N-S | B+ | Glutathione restoration; insulin sensitivity improvement (~31%) |
| C-H-O-N-S-Zn | A− | Metallothionein/ZnT8 biology; zinc-insulin crystallization |
| C-H-O-N-P | B | Phosphorylation cascades central to insulin signaling |
02 Peer-reviewed evidence
- PMID 11383627 — Zinc(II)-L-threonine complex lowers blood glucose in type-2 diabetic mice.
- PMID 18989849 — Zinc(II) complex normalizes hyperglycemia and reduces HbA1c (oral study).
- Zinc meta-analyses — fasting glucose reduction 8–23 mg/dL; HbA1c reduction 0.25–0.54%.
- Magnesium — meta-analyses of 24+ RCTs; HbA1c reduction up to 0.73% at 500 mg/day.
03 Safety-informed formulation
- Zinc capped at 30 mg/day (below the 40 mg UL).
- Copper 2 mg/day to prevent zinc-induced copper depletion.
- Zinc and magnesium dosed separately (AM/PM) to avoid absorption competition.
- Iron EXCLUDED — pro-oxidant risk to pancreatic beta cells.
04 What is in the package
- Discovery data (JSON) — compounds with probability scores and pathways.
- Known-properties report (peer-review corrected, evidence-graded).
- 30-day formula with pharmacist compounding specs (CAS numbers, USP-grade forms, batch weights, interactions).
- Patent application + four patent drawings (SVG).
- Discovery script for reproducing and extending the research.
Research disclaimer. These are research discoveries, NOT proven cures. No human clinical trial has tested these specific zinc-amino acid complexes as a diabetes treatment. Human evidence exists for simple zinc salts and magnesium (modest glycemic improvement). These are supplement-grade formulations, not pharmaceutical drugs, and not replacements for prescribed diabetes medications.
Inquiries
Christopher Gabriel Brown — Inventor & Licensor
Email and postal mail only — no phone calls, no brokers, no intermediaries.
crioneaka@outlook.com ·
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
crioneaka@outlook.com ·
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
Educational only. Not medical, legal, or regulatory advice; not a claim that any compound is a cure; not affiliated with or endorsed by the FDA or USPTO. Supplement-grade research, not an FDA-approved drug. Do not self-treat; consult a licensed physician. USA buyers only; sales subject to Georgia (Gwinnett County) law.
© 2026 Christopher Gabriel Brown. All rights reserved. “Cri-One” and “Licensed Research” are product designations of the licensor. Patents retained; not sold.
Write Your Own Review
Related Products
Check items to add to the cart or
